Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22342697 | 1.00 | TMPRSS2 (0.43) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL31571361 | 1.00 | TMPRSS2 (0.43) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL17719239 | 0.94 | TMPRSS2 (0.41) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL17761548 | 0.94 | TMPRSS2 (0.41) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL30002783 | 0.94 | TMPRSS2 (0.41) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL23859836 | 0.93 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL17712315 | 0.93 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL17712223 | 0.93 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL17760884 | 0.93 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL17760885 | 0.93 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| CN-115887465-A | Methods of treating arenaviridae and coronaviridae virus infections | 吉利德科学公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115844896-A | Methods of treating arenaviridae and coronaviridae virus infections | 吉利德科学公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4096678-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4088718-A1 | METHODS FOR TREATING CORONAVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11344565-B2 | Methods for the preparation of ribosides | GILEAD SCIENCES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| CN-114366745-A | Methods of treating arenaviridae and coronaviridae virus infections | 吉利德科学公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3349758-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-3212174-B1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9724360-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| WO-2017049060-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2016069827-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | TMPRSS2 3100/4885CYP3A4 2895/4885CYP2C9 4593/4885 |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | TMPRSS2 1951/4885CYP3A4 772/4885CYP2C9 2974/4885 |
| US-11344565-B2 | Methods for the preparation of ribosides | RUVBL2, RUVBL1, EIF2AK2 | TMPRSS2 3973/4885CYP3A4 2996/4885CYP2C9 4188/4885 |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | ACE, PNP, ACE2 | TMPRSS2 12/4885CYP3A4 1145/4885CYP2C9 2167/4885 |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | ACE2, ACE, PNP | TMPRSS2 6/4885CYP3A4 296/4885CYP2C9 476/4885 |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | TMPRSS2 12/4885CYP3A4 1145/4885CYP2C9 2167/4885 |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | ACE2, ACE, PNP | TMPRSS2 6/4885CYP3A4 296/4885CYP2C9 476/4885 |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | PNP, ACE, ACE2 | TMPRSS2 14/4885CYP3A4 1181/4885CYP2C9 2188/4885 |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | TMPRSS2 1951/4885CYP3A4 772/4885CYP2C9 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.